Strategic Growth Thirona’s AI-powered LungQ platform already deployed in over 1,200 hospitals worldwide and has substantial funding history, indicating a proven market fit and a willingness from investors to back expansion. This presents opportunities to cross-sell expanded AI capabilities, modules like LungQ AVX, and services to existing hospital networks and contract renewals.

Clinical Trial Focus The technology is positioned to accelerate imaging-based respiratory clinical trials and minimally invasive interventions. Target pharmaceutical companies, contract research organizations, and academic medical centers running thoracic imaging trials to offer standardized, automated, reproducible analysis across sites.

Strategic Partnerships Collaborations with research institutes, academic hospitals, pharma innovators, and MedTech partners suggest a receptive channel for co-development and integration opportunities. Explore value-add partnerships to embed LungQ into broader imaging workflows and multi-center studies.

Expansion Readiness Recent acquisition activity and ongoing funding indicate organizational momentum and potential for scale. Engage with global hospital networks and regional distributors to expand installation footprints, particularly in markets with active thoracic imaging programs.

Product Diversification LungQ AVX and broader airway/vascular phenotyping capabilities open doors to upsell premium modules, expanded phenotype analyses, and tailored benchmarking for pulmonology departments. Focus on selling enhanced quantification features to radiology chiefs and clinical researchers seeking deeper biomarker insights.